Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 1960
115th Congress(2017-2018)
A bill to repeal the amendments made to the Controlled Substances Act by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.
Introduced
Introduced
Introduced in Senate on Oct 16, 2017
Overview
Text
Introduced in Senate 
Oct 16, 2017
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in Senate(Oct 16, 2017)
Oct 16, 2017
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
S. 1960 (Introduced-in-Senate)


115th CONGRESS
1st Session
S. 1960


To repeal the amendments made to the Controlled Substances Act by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

IN THE SENATE OF THE UNITED STATES

October 16, 2017

Mrs. McCaskill (for herself, Mr. Manchin, and Ms. Hassan) introduced the following bill; which was read twice and referred to the Committee on the Judiciary

A BILL

To repeal the amendments made to the Controlled Substances Act by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Repeal of the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

(a) Registration process under the Controlled Substances Act.—Sections 1 and 2 of the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (Public Law 114–145; 130 Stat. 354) and the amendments made by such sections are repealed.

(b) Technical and conforming amendments.—

(1) DEFINITIONS.—

(A) FACTORS AS MAY BE RELEVANT TO AND CONSISTENT WITH THE PUBLIC HEALTH AND SAFETY.—Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by striking subsection (j).

(B) IMMINENT DANGER TO THE PUBLIC HEALTH OR SAFETY.—Section 304(d) of the Controlled Substances Act (21 U.S.C. 824(d)) is amended—

(i) by striking “(d)(1) The Attorney General” and inserting “(d) The Attorney General”; and

(ii) by striking paragraph (2).

(2) OPPORTUNITY TO SUBMIT CORRECTIVE ACTION PLAN PRIOR TO REVOCATION OR SUSPENSION.—Section 304(c) of the Controlled Substances Act (21 U.S.C. 824(c)) is amended—

(A) by striking paragraphs (2) through (5);

(B) by striking “(c)(1) Before” and inserting “(c) Before”; and

(C) by adding at the end the following: “The order to show cause shall contain a statement of the basis thereof and shall call upon the applicant or registrant to appear before the Attorney General at a time and place stated in the order, but in no event less than thirty days after the date of receipt of the order. Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance with subchapter II of chapter 5 of title 5, United States Code. Such proceedings shall be independent of, and not in lieu of, criminal prosecutions or other proceedings under this title or any other law of the United States.”.